Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 158

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee

Open access
Seymour, Lesley, Ivy, S. Percy, Sargent, Daniel, Spriggs, David, Baker, Laurence, Rubinstein, Larry, Ratain, Mark J., Le Blanc, Michael, Stewart, David, Crowley, John, Groshen, Susan, Humphrey, Jeffrey S., West, Pamela, Berry, Donald · 2010 · Clinical Cancer Research

Abstract

The optimal design of phase II studies continues to be the subject of vigorous debate, especially studies of newer molecularly targeted agents. The observations that many new therapeutics “fail” in definitive phase III studies, coupled with the numbers of new agents to be tested as well as the increasing costs and complexity of clinical trials, further emphasize the critical importance of robust and efficient phase II design. The Clinical Trial Design Task Force (CTD-TF) of the National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) has published a series of discussion papers on phase II trial design in Clinical Cancer Research. The IDSC has developed formal recommendations about aspects of phase II trial design that are the subject of frequent debate, such as endpoints (response versus progression-free survival), randomization (single-arm designs versus randomization), inclusion of biomarkers, biomarker-based patient enrichment strategies, and statistical design (e.g., two-stage designs versus multiple-group adaptive designs). Although these recommendations in general encourage the use of progression-free survival as the primary endpoint, randomization, inclusion of biomarkers, and incorporation of newer designs, we acknowledge that objective response as an endpoint and single-arm designs remain relevant in certain situations. The design of any clinical trial should always be carefully evaluated and justified based on characteristic specific to the situation. Clin Cancer Res; 16(6); 1764–9

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-09-3287

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 158

Metadata

Authors
Seymour, L., Ivy, S. P., Sargent, D., Spriggs, D., Baker, L., Rubinstein, L., Ratain, M. J., Le Blanc, M., Stewart, D., Crowley, J., Groshen, S., Humphrey, J. S., West, P., & Berry, D.
Venue
Clinical Cancer Research
Published
2010-03-14
Volume
16
Issue
6
Pages
1764-1769
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2128923437
Cited by
158
References
1
FWCI
15.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-09-3287
The paper
Seymour, L., Ivy, S. P., Sargent, D., Spriggs, D., Baker, L., Rubinstein, L., Ratain, M. J., Le Blanc, M., Stewart, D., Crowley, J., Groshen, S., Humphrey, J. S., West, P., & Berry, D. (2010). The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-09-3287

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.